inavolisib + endocrine therapy

Inavolisib + endocrine therapy is a combination treatment regimen primarily used for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced or metastatic breast cancer. Inavolisib (Itovebi) is a potent and selective small molecule inhibitor of the PI3Kα isoform that also promotes the degradation of the mutant p110α protein. Endocrine therapy (ET) in this context typically refers to selective estrogen receptor degraders (SERDs) like fulvestrant or aromatase inhibitors. The combination is designed to simultaneously target the PI3K and estrogen receptor signaling pathways, which are frequently co-activated in this cancer subtype. In October 2024, the FDA approved inavolisib in combination with palbociclib (a CDK4/6 inhibitor) and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR+/HER2- locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy.

Other names

inavolisib plus endocrine therapy